Effect of inflammation on cytochrome P450-mediated arachidonic acid metabolism and the consequences on cardiac hypertrophy

References

• Aboutabl ME, Zordoky BNM, El‐Kadi AOS. 2009. 3‐Methylcholanthrene and benzo (a) pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol. 158(7):1808–1819.
   PubMed Web of Science ®Google Scholar
• Aboutabl ME, Zordoky BNM, Hammock BD, El-Kadi AOS. 2011. Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo (a) pyrene. J Cardiovasc Pharmacol. 57(3):273–281.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. 2004. Nuclear factor-κB: the enemy within. Cancer Cell. 6(3):203–208.
   PubMed Web of Science ®Google Scholar
• Aitken AE, Lee C-M, Morgan ET. 2008. Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med. 44(6):1161–1168.
   PubMed Web of Science ®Google Scholar
• Aitken AE, Morgan ET. 2007. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 35(9):1687–1693.
   PubMed Web of Science ®Google Scholar
• Aitken AE, Richardson TA, Morgan ET. 2006. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 46:123–149.
   PubMed Web of Science ®Google Scholar
• Alammari AH, Shoieb SM, Maayah ZH, El-Kadi AOS. 2020. Fluconazole represses cytochrome P450 1B1 and its associated arachidonic acid metabolites in the heart and protects against angiotensin II-induced cardiac hypertrophy. J Pharm Sci. 109(7):2321–2335.
   PubMed Web of Science ®Google Scholar
• Alavi MS, Shamsizadeh A, Azhdari-Zarmehri H, Roohbakhsh A. 2018. Orphan G protein-coupled receptors: the role in CNS disorders. Biomed Pharmacother. 98:222–232.
   PubMed Web of Science ®Google Scholar
• Aliwarga T, Guo X, Evangelista EA, Lemaitre RN, Sotoodehnia N, Gharib SA, Zeldin DC, Liu Q, Totah RA. 2020. Higher epoxyeicosatrienoic acids in cardiomyocytes-specific CYP2J2 transgenic mice are associated with improved myocardial remodeling. Biomedicines. 8(6):144.
   PubMed Web of Science ®Google Scholar
• Alsaad AMS, Zordoky BNM, El-Sherbeni AA, El-Kadi AOS. 2012. Chronic doxorubicin cardiotoxicity modulates cardiac cytochrome P450-mediated arachidonic acid metabolism in rats. Drug Metab Dispos. 40(11):2126–2135.
   PubMed Web of Science ®Google Scholar
• Alsaad AMS, Zordoky BNM, Tse MMY, El-Kadi AOS. 2013. Role of cytochrome P450–mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy. Drug Metab Rev. 45(2):173–195.
   PubMed Web of Science ®Google Scholar
• Althurwi HN, Elshenawy OH, El-Kadi AOS. 2014. Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 63(2):167–177.
   PubMed Web of Science ®Google Scholar
• Althurwi HN, Maayah ZH, Elshenawy OH, El-Kadi AOS. 2015. Early changes in cytochrome P450s and their associated arachidonic acid metabolites play a crucial role in the initiation of cardiac hypertrophy induced by isoproterenol. Drug Metab Dispos. 43(8):1254–1266.
   PubMed Web of Science ®Google Scholar
• Althurwi HN, Tse MMY, Abdelhamid G, Zordoky BNM, Hammock BD, El‐Kadi AOS. 2013. Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline‐induced cardiac hypertrophy. Br J Pharmacol. 168(8):1794–1807.
   PubMed Web of Science ®Google Scholar
• Anthony SR, Guarnieri AR, Gozdiff A, Helsley RN, Phillip Owens A, III, Tranter M. 2019. Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis. Clin Sci. 133(22):2329–2344.
   Web of Science ®Google Scholar
• Anwar-Mohamed A, Elshenawy OH, El-Sherbeni AA, Abdelrady M, El-Kadi AOS. 2014. Acute arsenic treatment alters arachidonic acid and its associated metabolite levels in the brain of C57Bl/6 mice. Can J Physiol Pharmacol. 92(8):693–702.
   PubMed Web of Science ®Google Scholar
• Anwar-Mohamed A, Zordoky BNM, Aboutabl ME, El-Kadi AOS. 2010. Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res. 61(5):410–418.
   PubMed Web of Science ®Google Scholar
• Ashkar S, Mesentsev A, Zhang W-X, Mastyugin V, Dunn MW, Laniado-Schwartzman M. 2004. Retinoic acid induces corneal epithelial CYP4B1 gene expression and stimulates the synthesis of inflammatory 12-hydroxyeicosanoids. J Ocul Pharmacol Ther. 20(1):65–74.
   PubMed Web of Science ®Google Scholar
• Bao Y, Wang X, Li W, Huo D, Shen X, Han Y, Tan J, Zeng Q, Sun C. 2011. 20-HETE induces apoptosis in neonatal rat cardiomyocytes through mitochondrial-dependent pathways. J Cardiovasc Pharmacol. 57(3):294–301.
   PubMed Web of Science ®Google Scholar
• Barbosa-Sicard E, Markovic M, Honeck H, Christ B, Muller DN, Schunck W-H. 2005. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun. 329(4):1275–1281.
   PubMed Web of Science ®Google Scholar
• Bednar MM, Gross CE, Balazy M, Falck JR. 1997. Antineutrophil strategies. Neurology. 49(5 Suppl 4):S20–S22.
   PubMed Web of Science ®Google Scholar
• Bednar MM, Gross CE, Balazy MK, Belosludtsev Y, Colella DT, Falck JR, Balazy M. 2000. 16 (R)-hydroxy-5, 8, 11, 14-eicosatetraenoic acid, a new arachidonate metabolite in human polymorphonuclear leukocytes. Biochem Pharmacol. 60(3):447–455.
   PubMed Web of Science ®Google Scholar
• Bednar MM, Gross CE, Russell SR, Fuller SP, Ahern TP, Howard DB, Falck JR, Reddy KM, Balazy M. 2000. 16 (R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocytes and reduces intracranial pressure in a rabbit model of thromboembolic stroke. Neurosurgery. 47(6):1410–1419.
   PubMed Web of Science ®Google Scholar
• Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. 2002. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun. 293(1):145–149.
   PubMed Web of Science ®Google Scholar
• Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I. 2007. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP) 1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics. 17(9):731–742.
   PubMed Web of Science ®Google Scholar
• Bishop‐Bailey D. 2000. Peroxisome proliferator‐activated receptors in the cardiovascular system. Br J Pharmacol. 129(5):823–834.
   PubMed Web of Science ®Google Scholar
• Bocher V, Chinetti G, Fruchart J-C, Staels B. 2002. Rôles des “Peroxisome Proliferator-Activated Receptors” (PPARs) dans la régulation du métabolisme des lipides et le contrôle de l’inflammation. J Soc Biol. 196(1):47–52.
   PubMedGoogle Scholar
• Bottex-Gauthier C, Pollet S, Favier A, Vidal DR. 2002. The Rel/NF-kappa-B transcription factors: complex role in cell regulation. Pathol Biol. 50(3):204–211.
   PubMedGoogle Scholar
• Brash AR. 1999. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 274(34):23679–23682.
   PubMed Web of Science ®Google Scholar
• Burgess A, Vanella L, Bellner L, Schwartzman ML, Abraham NG. 2012. Epoxyeicosatrienoic acids and heme oxygenase-1 interaction attenuates diabetes and metabolic syndrome complications. Prostaglandins Other Lipid Mediat. 97(1–2):1–16.
   PubMed Web of Science ®Google Scholar
• Burhop KE, Selig WM, Malik AB. 1988. Monohydroxyeicosatetraenoic acids (5-HETE and 15-HETE) induce pulmonary vasoconstriction and edema. Circ Res. 62(4):687–698.
   PubMed Web of Science ®Google Scholar
• Bystrom J, Wray JA, Sugden MC, Holness MJ, Swales KE, Warner TD, Edin ML, Zeldin DC, Gilroy DW, Bishop-Bailey D. 2011. Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One. 6(10):e26591.
   PubMed Web of Science ®Google Scholar
• Caligiuri SPB, Rodriguez-Leyva D, Aukema HM, Ravandi A, Weighell W, Guzman R, Pierce GN. 2016. Dietary flaxseed reduces central aortic blood pressure without cardiac involvement but through changes in plasma oxylipins. Hypertension. 68(4):1031–1038.
   PubMed Web of Science ®Google Scholar
• Campbell WB, Fleming I. 2010. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch Eur J Physiol. 459(6):881–895.
   PubMed Web of Science ®Google Scholar
• Campbell WB, Gebremedhin D, Pratt PF, Harder DR. 1996. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 78(3):415–423.
   PubMed Web of Science ®Google Scholar
• Campbell WB, Imig JD, Schmitz JM, Falck JR. 2017. Drugs in the pipeline series: orally active epoxyeicosatrienoic acid analogs. J Cardiovasc Pharmacol. 70(4):211–224.
   PubMed Web of Science ®Google Scholar
• Campbell WB. 2000. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci. 21(4):125–127.
   PubMed Web of Science ®Google Scholar
• Cao J, Singh SP, McClung JA, Joseph G, Vanella L, Barbagallo I, Jiang H, Falck JR, Arad M, Shapiro JI, et al. 2017. EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice. Am J Physiol Circ Physiol. 313(2):H368–H380.
   PubMed Web of Science ®Google Scholar
• Cao J, Tsenovoy PL, Thompson EA, Falck JR, Touchon R, Sodhi K, Rezzani R, Shapiro JI, Abraham NG. 2015. Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway. Prostaglandins Other Lipid Mediat. 116-117:76–86.
   PubMed Web of Science ®Google Scholar
• Capdevila J, Marnett LJ, Chacos N, Prough RA, Estabrook RW. 1982. Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids. Proc Natl Acad Sci U S A. 79(3):767–770.
   PubMed Web of Science ®Google Scholar
• Capdevila JH, Falck JR, Harris RC. 2000. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 41(2):163–181.
   PubMed Web of Science ®Google Scholar
• Carroll MA, Balazy M, Huang D-D, Rybalova S, Falck JR, Mcgiff JC. 1997. Cytochrome P450-derived renal HETEs: storage and release. Kidney Int. 51(6):1696–1702.
   PubMed Web of Science ®Google Scholar
• Certíková Chábová V, Kramer HJ, Vanecková I, Vernerová Z, Eis V, Tesar V, Skaroupková P, Thumová M, Schejbalová S, Husková Z, et al. 2007. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol. 47(2–3):145–159.
   PubMed Web of Science ®Google Scholar
• Certíková Chábová V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerová Z, Vanourková Z, Kopkan L, Kramer HJ, Falck JR, et al. 2010. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertensioninduced end-organ damage in Ren-2 transgenic rats. Clin Sci. 118(10):617–632.
   Web of Science ®Google Scholar
• Červenka L, Melenovský V, Husková Z, Škaroupková P, Nishiyama A, Sadowski J. 2015. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in R en‐2 transgenic hypertensive rats with aorto‐caval fistula. Clin Exp Pharmacol Physiol. 42(7):795–807.
   PubMed Web of Science ®Google Scholar
• Chadderdon SM, Belcik JT, Bader L, Kievit P, Grove KL, Lindner JR. 2016. Vasoconstrictor eicosanoids and impaired microvascular function in inactive and insulin-resistant primates. Int J Obes. 40(10):1600–1603.
   Web of Science ®Google Scholar
• Chehal MK, Granville DJ. 2006. Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction. Can J Physiol Pharmacol. 84(1):15–20.
   PubMed Web of Science ®Google Scholar
• Chen D, Whitcomb R, MacIntyre E, Tran V, Do ZN, Sabry J, Patel DV, Anandan SK, Gless R, Webb HK. 2012. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single‐and multiple‐dose studies in healthy human subjects. J Clin Pharmacol. 52(3):319–328.
   PubMed Web of Science ®Google Scholar
• Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. 2018. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 9(6):7204–7218. https://pubmed.ncbi.nlm.nih.gov/29467962.
   PubMedGoogle Scholar
• Chen R, Jiang J, Xiao X, Wang D. 2005. Effects of epoxyeicosatrienoic acids on levels of eNOS phosphorylation and relevant signaling transduction pathways involved. Sci China C Life Sci. 48(5):495–505.
   PubMedGoogle Scholar
• Cheng J, Ou J-S, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA, Jr, Schwartzman ML. 2008. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol. 294(2):H1018–H1026.
   PubMed Web of Science ®Google Scholar
• Cheng J, Wu C-C, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D, Schwartzman ML. 2010. 20-Hydroxy-5, 8, 11, 14-eicosatetraenoic acid mediates endothelial dysfunction via IκB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther. 332(1):57–65.
   PubMed Web of Science ®Google Scholar
• Chiamvimonvat N, Ho C-M, Tsai H-J, Hammock BD. 2007. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol. 50(3):225–237.
   PubMed Web of Science ®Google Scholar
• Choudhary D, Jansson I, Schenkman JB, Sarfarazi M, Stoilov I. 2003. Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch Biochem Biophys. 414(1):91–100.
   PubMed Web of Science ®Google Scholar
• Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. 2004. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 32(8):840–847.
   PubMed Web of Science ®Google Scholar
• Ciepiela P, Bączkowski T, Drozd A, Kazienko A, Stachowska E, Kurzawa R. 2015. Arachidonic and linoleic acid derivatives impact oocyte ICSI fertilization–a prospective analysis of follicular fluid and a matched oocyte in a ‘one follicle–one retrieved oocyte–one resulting embryo’ investigational setting. PLoS One. 10(3):e0119087.
   PubMed Web of Science ®Google Scholar
• Cui X, Kalsotra A, Robida AM, Matzilevich D, Moore AN, Boehme CL, Morgan ET, Dash PK, Strobel HW. 2003. Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation. Biochim Biophys Acta (BBA)-General Subj. 1619(3):325–331.
   PubMed Web of Science ®Google Scholar
• Daikh BE, Lasker JM, Raucy JL, Koop DR. 1994. Regio-and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther. 271(3):1427–1433.
   PubMed Web of Science ®Google Scholar
• Das A, Weigle AT, Arnold WR, Kim JS, Carnevale LN, Huff HC. 2020. CYP2J2 molecular recognition: a new axis for therapeutic design. Pharmacol Ther. 215:107601.
   PubMed Web of Science ®Google Scholar
• Delcayre C, Silvestre J-S. 1999. Aldosterone and the heart: towards a physiological function? Cardiovasc Res. 43(1):7–12.
   PubMed Web of Science ®Google Scholar
• Delerive P, Fruchart JC, Staels B. 2001. Eurosterone meeting–peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 169(3):453–459.
   PubMed Web of Science ®Google Scholar
• Deng Y, Theken KN, Lee CR. 2010. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol. 48(2):331–341.
   PubMed Web of Science ®Google Scholar
• Dhanya BL, Swathy RP, Indira M. 2014. Selenium downregulates oxidative stress-induced activation of leukotriene pathway in experimental rats with diabetic cardiac hypertrophy. Biol Trace Elem Res. 161(1):107–115.
   PubMed Web of Science ®Google Scholar
• Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. 2005. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 46(6):842–848.
   PubMed Web of Science ®Google Scholar
• Du G, Lv J, He L, Ma Y. 2011. Influence of silencing soluble epoxide hydrolase with RNA interference on cardiomyocytes apoptosis induced by doxorubicin. J Huazhong Univ Sci Technolog Med Sci. 31(3):324–328.
   PubMedGoogle Scholar
• Dyerberg J, Bang HO. 1979. Lipid metabolism, atherogenesis, and haemostasis in Eskimos: the role of the prostaglandin-3 family. Pathophysiol Haemost Thromb. 8(3–5):227–233.
   Google Scholar
• Elkhatali S, El-Sherbeni AA, Elshenawy OH, Abdelhamid G, El-Kadi AOS. 2015. 19-Hydroxyeicosatetraenoic acid and isoniazid protect against angiotensin II-induced cardiac hypertrophy. Toxicol Appl Pharmacol. 289(3):550–559.
   PubMed Web of Science ®Google Scholar
• Elkhatali S, Maayah ZH, El-Sherbeni AA, Elshenawy OH, Abdelhamid G, Shoieb SM, El-Kadi AOS. 2017. Inhibition of mid-chain HETEs protects against angiotensin II–induced cardiac hypertrophy. J Cardiovasc Pharmacol. 70(1):16–24.
   PubMed Web of Science ®Google Scholar
• El-Sherbeni AA, El-Kadi AOS. 2014. Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy. Biochem Pharmacol. 87(3):456–466.
   PubMed Web of Science ®Google Scholar
• El-Sherbeni AA, El-Kadi AOS. 2017. Microsomal cytochrome P450 as a target for drug discovery and repurposing. Drug Metab Rev. 49(1):1–17.
   PubMed Web of Science ®Google Scholar
• Enayetallah AE, French RA, Thibodeau MS, Grant DF. 2004. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem. 52(4):447–454.
   PubMed Web of Science ®Google Scholar
• Erten Y, Tulmac M, Derici U, Pasaoglu H, Reis KA, Bali M, Arinsoy T, Cengel A, Sindel S. 2005. An association between inflammatory state and left ventricular hypertrophy in hemodialysis patients. Ren Fail. 27(5):581–589.
   PubMed Web of Science ®Google Scholar
• Evangelista EA, Aliwarga T, Sotoodehnia N, Jensen PN, McKnight B, Lemaitre RN, Totah RA, Gharib SA. 2020. CYP2J2 modulates diverse transcriptional programs in adult human cardiomyocytes. Sci Rep. 10(1):5329.
   PubMed Web of Science ®Google Scholar
• Falck JR, Reddy LM, Reddy YK, Bondlela M, Krishna UM, Ji Y, Sun J, Liao JK. 2003. 11, 12-Epoxyeicosatrienoic acid (11, 12-EET): structural determinants for inhibition of TNF-α-induced VCAM-1 expression. Bioorg Med Chem Lett. 13(22):4011–4014.
   PubMed Web of Science ®Google Scholar
• Fang L, Ellims AH, Beale AL, Taylor AJ, Murphy A, Dart AM. 2017. Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am J Transl Res. 9(11):5063–5073.
   PubMed Web of Science ®Google Scholar
• Fer M, Dréano Y, Lucas D, Corcos L, Salaün J-P, Berthou F, Amet Y. 2008. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys. 471(2):116–125.
   PubMed Web of Science ®Google Scholar
• Fernández-Velasco M, González-Ramos S, Boscá L. 2014. Involvement of monocytes/macrophages as key factors in the development and progression of cardiovascular diseases. Biochem J. 458(2):187–193.
   PubMed Web of Science ®Google Scholar
• Fleming I, Michaelis UR, Bredenkötter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R. 2001. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res. 88(1):44–51.
   PubMed Web of Science ®Google Scholar
• Fleming I. 2011. The cytochrome P450 pathway in angiogenesis and endothelial cell biology. Cancer Metastasis Rev. 30(3–4):541–555.
   PubMed Web of Science ®Google Scholar
• Garcia V, Gilani A, Shkolnik B, Pandey V, Zhang FF, Dakarapu R, Gandham SK, Reddy NR, Graves JP, Gruzdev A, et al. 2017. 20-HETE signals through G-protein–coupled receptor GPR75 (Gq) to affect vascular function and trigger hypertension. Circ Res. 120(11):1776–1788.
   PubMed Web of Science ®Google Scholar
• Gerges SH, El-Kadi AOS. 2022. Sex differences in eicosanoid formation and metabolism: a possible mediator of sex discrepancies in cardiovascular diseases. Pharmacol Ther. 234:108046.
   PubMedGoogle Scholar
• Gerges SH, El-Kadi AOS. 2022. Sexual dimorphism in the expression of cytochrome P450 enzymes in rat heart, liver, kidney, lung, brain, and small intestine. Drug Metab Dispos. 51:DMD-AR-2022-000915.
   Web of Science ®Google Scholar
• Gonzalez-Fernandez E, Staursky D, Lucas K, Nguyen BV, Li M, Liu Y, Washington C, Coolen LM, Fan F, Roman RJ. 2020. 20-HETE enzymes and receptors in the neurovascular unit: implications in cerebrovascular disease. Front Neurol. 11:983.
   PubMed Web of Science ®Google Scholar
• González-Núñez D, Claria J, Rivera F, Poch E. 2001. Increased levels of 12 (S)-HETE in patients with essential hypertension. Hypertension. 37(2):334–338.
   PubMed Web of Science ®Google Scholar
• Gross ER, Nithipatikom K, Hsu AK, Peart JN, Falck JR, Campbell WB, Gross GJ. 2004. Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol. 37(6):1245–1249.
   PubMed Web of Science ®Google Scholar
• Gruntman AM, Flotte TR. 2018. The rapidly evolving state of gene therapy. FASEB J. 32(4):1733–1740.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 2008. Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 21(1):70–83.
   PubMed Web of Science ®Google Scholar
• Harris TR, Li N, Chiamvimonvat N, Hammock BD. 2008. The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy. Congest Heart Fail. 14(4):219–224.
   PubMedGoogle Scholar
• He Z, Zhang X, Chen C, Wen Z, Hoopes SL, Zeldin DC, Wang DW. 2015. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II. Cardiovasc Res. 105(3):304–317.
   PubMed Web of Science ®Google Scholar
• Hercule HC, Schunck W-H, Gross V, Seringer J, Leung FP, Weldon SM, da Costa Goncalves AC, Huang Y, Luft FC, Gollasch M. 2009. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol. 29(1):54–60.
   PubMed Web of Science ®Google Scholar
• Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen REW, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, et al. 2013. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 128(13):1420–1432.
   PubMed Web of Science ®Google Scholar
• Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, et al. 2009. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 11(2):119–129.
   PubMed Web of Science ®Google Scholar
• Hildreth K, Kodani SD, Hammock BD, Zhao L. 2020. Cytochrome P450-derived linoleic acid metabolites EpOMEs and DiHOMEs: a review of recent studies. J Nutr Biochem. 86:108484.
   PubMed Web of Science ®Google Scholar
• Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, Müller W, Scherr M, Theilmeier G, Ernst M, et al. 2010. Continuous glycoprotein-130–mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 122(2):145–155.
   PubMed Web of Science ®Google Scholar
• Hirota H, Yoshida K, Kishimoto T, Taga T. 1995. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 92(11):4862–4866.
   PubMed Web of Science ®Google Scholar
• Hofmann U, Frantz S. 2013. How can we cure a heart “in flame”? A translational view on inflammation in heart failure. Basic Res Cardiol. 108(4):356. https://pubmed.ncbi.nlm.nih.gov/23740214.
   PubMed Web of Science ®Google Scholar
• Huang C-C, Chang M-T, Leu H-B, Yin W-H, Tseng W-K, Wu Y-W, Lin T-H, Yeh H-I, Chang K-C, Wang J-H. 2020. Association of arachidonic acid-derived lipid mediators with subsequent onset of acute myocardial infarction in patients with coronary artery disease. Sci Rep. 10(1):8105.
   PubMed Web of Science ®Google Scholar
• Huang H, Morisseau C, Wang J, Yang T, Falck JR, Hammock BD, Wang M-H. 2007. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol. 293(1):F342–F349.
   PubMed Web of Science ®Google Scholar
• Hutchens MP, Nakano T, Dunlap J, Traystman RJ, Hurn PD, Alkayed NJ. 2008. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation. 76(1):89–94.
   PubMed Web of Science ®Google Scholar
• Ignatov A, Robert J, Gregory‐Evans C, Schaller HC. 2006. RANTES stimulates Ca2+ mobilization and inositol trisphosphate (IP3) formation in cells transfected with G protein‐coupled receptor 75. Br J Pharmacol. 149(5):490–497.
   PubMed Web of Science ®Google Scholar
• Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. 2002. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 39(2 Pt 2):690–694.
   PubMed Web of Science ®Google Scholar
• Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim I-H, Watanabe T, Hammock BD. 2005. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 46(4):975–981.
   PubMed Web of Science ®Google Scholar
• Imig JD. 2005. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 289(3):F496–F503.
   PubMed Web of Science ®Google Scholar
• Imig JD. 2012. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 92(1):101–130.
   PubMed Web of Science ®Google Scholar
• Imig JD. 2018. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther. 192:1–19.
   PubMed Web of Science ®Google Scholar
• Imig JD. 2019. Epoxyeicosanoids in hypertension. Physiol Res. 68(5):695–704.
   PubMed Web of Science ®Google Scholar
• Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD. 2007. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 82(1–4):42–49.
   PubMed Web of Science ®Google Scholar
• Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, Laniado-Schwartzman M. 2008. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-κB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther. 324(1):103–110.
   PubMed Web of Science ®Google Scholar
• Issan Y, Hochhauser E, Guo A, Gotlinger KH, Kornowski R, Leshem-Lev D, Lev E, Porat E, Snir E, Thompson CI, et al. 2013. Elevated level of pro-inflammatory eicosanoids and EPC dysfunction in diabetic patients with cardiac ischemia. Prostaglandins Other Lipid Mediat. 100-101:15–21.
   PubMed Web of Science ®Google Scholar
• Ivanov I, Romanov S, Ozdoba C, Holzhütter HG, Myagkova G, Kuhn H. 2004. Enantioselective substrate specificity of 15-lipoxygenase 1. Biochemistry. 43(50):15720–15728.
   PubMed Web of Science ®Google Scholar
• Jamieson KL, Endo T, Darwesh AM, Samokhvalov V, Seubert JM. 2017. Cytochrome P450-derived eicosanoids and heart function. Pharmacol Ther. 179:47–83.
   PubMed Web of Science ®Google Scholar
• Jennings BL, Sahan-Firat S, Estes AM, Das K, Farjana N, Fang XR, Gonzalez FJ, Malik KU. 2010. Cytochrome P450 1B1 contributes to angiotensin II–induced hypertension and associated pathophysiology. Hypertension. 56(4):667–674.
   PubMed Web of Science ®Google Scholar
• Jiang J-G, Chen C-L, Card JW, Yang S, Chen J-X, Fu X-N, Ning Y-G, Xiao X, Zeldin DC, Wang DW. 2005. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 65(11):4707–4715.
   PubMed Web of Science ®Google Scholar
• Jiang JG, Chen RJ, Xiao B, Yang S, Wang JN, Wang Y, Cowart LA, Xiao X, Wang DW, Xia Y. 2007. Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat. 82(1–4):162–174.
   PubMed Web of Science ®Google Scholar
• Johnson AL, Edson KZ, Totah RA, Rettie AE. 2015. Cytochrome P450 ω-hydroxylases in inflammation and cancer. Adv Pharmacol. 74:223–262.
   PubMedGoogle Scholar
• Kalsotra A, Anakk S, Brommer CL, Kikuta Y, Morgan ET, Strobel HW. 2007. Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. Arch Biochem Biophys. 461(1):104–112.
   PubMed Web of Science ®Google Scholar
• Kalsotra A, Zhao J, Anakk S, Dash PK, Strobel HW. 2007. Brain trauma leads to enhanced lung inflammation and injury: evidence for role of P4504Fs in resolution. J Cereb Blood Flow Metab. 27(5):963–974.
   PubMed Web of Science ®Google Scholar
• Kaur S, Gill SS. 1985. Age-related changes in the activities of epoxide hydrolases in different tissues of mice. Drug Metab Dispos. 13(6):711–715.
   PubMed Web of Science ®Google Scholar
• Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Takahashi H, Okada S, Tateno K, Moriya J, Yokoyama M, et al. 2009. Cardiac 12/15 lipoxygenase–induced inflammation is involved in heart failure. J Exp Med. 206(7):1565–1574.
   PubMed Web of Science ®Google Scholar
• Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. 2001. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-α and lipopolysaccharide. J Biol Chem. 276(43):39638–39644.
   PubMed Web of Science ®Google Scholar
• Keserü B, Barbosa-Sicard E, Popp R, Fisslthaler B, Dietrich A, Gudermann T, Hammock BD, Falck JR, Weissmann N, Busse R, et al. 2008. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. Faseb J. 22(12):4306–4315.
   PubMed Web of Science ®Google Scholar
• Khan MAH, Pavlov TS, Christain SV, Neckář J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD. 2014. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci. 127(7):463–474.
   Web of Science ®Google Scholar
• Khan MZ, He L. 2017. Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors. Psychopharmacology. 234(8):1181–1207.
   PubMed Web of Science ®Google Scholar
• Kim DH, Vanella L, Inoue K, Burgess A, Gotlinger K, Manthati VL, Koduru SR, Zeldin DC, Falck JR, Schwartzman ML, et al. 2010. Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell–derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARγ. Stem Cells Dev. 19(12):1863–1873.
   PubMed Web of Science ®Google Scholar
• Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C. 2003. Repression of farnesoid X receptor during the acute phase response. J Biol Chem. 278(11):8988–8995.
   PubMed Web of Science ®Google Scholar
• Kiss L, Bier J, Röder Y, Weissmann N, Grimminger F, Seeger W. 2008. Direct and simultaneous profiling of epoxyeicosatrienoic acid enantiomers by capillary tandem column chiral-phase liquid chromatography with dual online photodiode array and tandem mass spectrometric detection. Anal Bioanal Chem. 392(4):717–726.
   PubMed Web of Science ®Google Scholar
• Kompa AR, Wang BH, Xu G, Zhang Y, Ho P-Y, Eisennagel S, Thalji RK, Marino JP, Kelly DJ, Behm DJ, et al. 2013. Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. Int J Cardiol. 167(1):210–219.
   PubMed Web of Science ®Google Scholar
• Kong EKC, Huang Y, Sanderson JE, Chan K-B, Yu S, Yu C-M. 2010. Baicalein and wogonin inhibit collagen deposition in SHR and WKY cardiac fibroblast cultures. BMB Rep. 43(4):297–303.
   PubMed Web of Science ®Google Scholar
• Kong EKC, Yu S, Sanderson JE, Chen K-B, Huang Y, Yu C-M. 2011. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats. Eur J Pharmacol. 658(2–3):175–181.
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Xu F. 2005. Regulation and inhibition of arachidonic acid [omega]-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol. 45:413–438.
   PubMed Web of Science ®Google Scholar
• Kuehl FA, Jr, Egan RW. 1980. Prostaglandins, arachidonic acid, and inflammation. Science. 210(4473):978–984.
   PubMed Web of Science ®Google Scholar
• Kuusisto J, Kärjä V, Sipola P, Kholová I, Peuhkurinen K, Jääskeläinen P, Naukkarinen A, Ylä-Herttuala S, Punnonen K, Laakso M. 2012. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 98(13):1007–1013.
   PubMed Web of Science ®Google Scholar
• Lee C-M, Kim B-Y, Li L, Morgan ET. 2008. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem. 283(2):889–898.
   PubMed Web of Science ®Google Scholar
• Levick SP, Loch DC, Taylor SM, Janicki JS. 2007. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol. 178(2):641–646.
   PubMed Web of Science ®Google Scholar
• Levis BE, Binkley PF, Shapiro CL. 2017. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol. 18(8):e445–e456.
   PubMed Web of Science ®Google Scholar
• Li N, Liu J-Y, Timofeyev V, Qiu H, Hwang SH, Tuteja D, Lu L, Yang J, Mochida H, Low R, et al. 2009. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J Mol Cell Cardiol. 47(6):835–845.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tang H, Liu X, Chen H, Feng N, Zhang J, Wang C, Qiu M, Yang J, Zhou X. 2019. Frontline Science: reprogramming COX‐2, 5‐LOX, and CYP4A‐mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis. J Leukoc Biol. 105(1):11–24.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Y, Schmelzer K, Lee T-S, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, et al. 2005. The antiinflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A. 102(46):16747–16752.
   PubMed Web of Science ®Google Scholar
• López-Vicario C, Alcaraz-Quiles J, García-Alonso V, Rius B, Hwang SH, Titos E, Lopategi A, Hammock BD, Arroyo V, Clària J. 2015. Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides. Proc Natl Acad Sci U S A. 112(2):536–541.
   PubMed Web of Science ®Google Scholar
• Lv X, Wan J, Yang J, Cheng H, Li Y, Ao Y, Peng R. 2008. Cytochrome P450 ω-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol. 596(1–3):118–126.
   PubMed Web of Science ®Google Scholar
• Maayah ZH, Abdelhamid G, El-Kadi AOS. 2015. Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-κB. Cell Biol Toxicol. 31(4–5):241–259.
   PubMed Web of Science ®Google Scholar
• Maayah ZH, Althurwi HN, Abdelhamid G, Lesyk G, Jurasz P, El-Kadi AOS. 2016. CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism. Pharmacol Res. 105:28–43.
   PubMed Web of Science ®Google Scholar
• Maayah ZH, Althurwi HN, El-Sherbeni AA, Abdelhamid G, Siraki AG, El-Kadi AOS. 2017. The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol. Mol Cell Biochem. 429(1–2):151–165.
   PubMed Web of Science ®Google Scholar
• Maayah ZH, El-Kadi AOS. 2016. 5-, 12-and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK-and NF-κB-dependent mechanism. Arch Toxicol. 90(2):359–373.
   PubMed Web of Science ®Google Scholar
• Maayah ZH, Elshenawy OH, Althurwi HN, Abdelhamid G, El-Kadi AOS. 2015. Human fetal ventricular cardiomyocyte, RL-14 cell line, is a promising model to study drug metabolizing enzymes and their associated arachidonic acid metabolites. J Pharmacol Toxicol Methods. 71:33–41.
   PubMed Web of Science ®Google Scholar
• Maayah ZH, Levasseur J, Siva Piragasam R, Abdelhamid G, Dyck JRB, Fahlman RP, Siraki AG, El-Kadi AOS. 2018. 2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy. Sci Rep. 8(1):1–15.
   PubMed Web of Science ®Google Scholar
• Maciejewska D, Ossowski P, Drozd A, Ryterska K, Jamioł-Milc D, Banaszczak M, Kaczorowska M, Sabinicz A, Raszeja-Wyszomirska J, Stachowska E. 2015. Metabolites of arachidonic acid and linoleic acid in early stages of non-alcoholic fatty liver disease—A pilot study. Prostaglandins Other Lipid Mediat. 121(Pt B):184–189.
   PubMed Web of Science ®Google Scholar
• Malaplate-Armand C, Ferrari L, Masson C, Siest G, Batt AM. 2003. Astroglial CYP1B1 up-regulation in inflammatory/oxidative toxic conditions: IL-1β effect and protection by N-acetylcysteine. Toxicol Lett. 138(3):243–251.
   PubMed Web of Science ®Google Scholar
• Mandy MY, Aboutabl ME, Althurwi HN, Elshenawy OH, Abdelhamid G, El-Kadi AOS. 2013. Cytochrome P450 epoxygenase metabolite, 14, 15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line. Vascul Pharmacol. 58(5–6):363–373.
   PubMed Web of Science ®Google Scholar
• Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. 2012. Inflammation in myocardial diseases. Circ Res. 110(1):126–144.
   PubMed Web of Science ®Google Scholar
• Marino J, Joseph P. 2009. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr Top Med Chem. 9(5):452–463.
   PubMed Web of Science ®Google Scholar
• Matavelli LC, Huang J, Siragy HM. 2011. Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 57(2):308–313.
   PubMed Web of Science ®Google Scholar
• Matsumura N, Takahara S, Maayah ZH, Parajuli N, Byrne NJ, Shoieb SM, Soltys C-LM, Beker DL, Masson G, El-Kadi AOS, et al. 2018. Resveratrol improves cardiac function and exercise performance in MI-induced heart failure through the inhibition of cardiotoxic HETE metabolites. J Mol Cell Cardiol. 125:162–173.
   PubMed Web of Science ®Google Scholar
• May MJ, Ghosh S. 1998. Signal transduction through NF-κB. Immunol Today. 19(2):80–88.
   PubMedGoogle Scholar
• McKay LI, Cidlowski JA. 1999. Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr Rev. 20(4):435–459.
   PubMed Web of Science ®Google Scholar
• Merabet N, Bellien J, Glevarec E, Nicol L, Lucas D, Remy-Jouet I, Bounoure F, Dreano Y, Wecker D, Thuillez C, et al. 2012. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure. J Mol Cell Cardiol. 52(3):660–666.
   PubMed Web of Science ®Google Scholar
• Minamiyama Y, Takemura S, Akiyama T, Imaoka S, Inoue M, Funae Y, Okada S. 1999. Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 452(3):165–169.
   PubMed Web of Science ®Google Scholar
• Miyata N, Seki T, Tanaka Y, Omura T, Taniguchi K, Doi M, Bandou K, Kametani S, Sato M, Okuyama S, et al. 2005. Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N′-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther. 314(1):77–85.
   PubMed Web of Science ®Google Scholar
• Monsen ER, Okey R, Lyman RL. 1962. Effect of diet and sex on the relative lipid composition of plasma and red blood cells in the rat. Metabolism. 11:1113–1124.
   PubMed Web of Science ®Google Scholar
• Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gösele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, et al. 2008. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet. 40(5):529–537.
   PubMed Web of Science ®Google Scholar
• Morgan ET. 2001. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos. 29(3):207–212.
   PubMed Web of Science ®Google Scholar
• Morgan ET. 2009. Impact of infectious and inflammatory disease on cytochrome P450–mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 85(4):434–438.
   PubMed Web of Science ®Google Scholar
• Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. 2008. EET displays anti-inflammatory effects in TNF-α–stimulated human bronchi: putative Role of CPI-17. Am J Respir Cell Mol Biol. 38(2):192–201.
   PubMed Web of Science ®Google Scholar
• Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, Kumar M, Hughes WM, Metreveli N, Rosenberger DSE, Singh M, et al. 2008. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP‐9 via inhibition of NF‐κβ in hyperhomocysteinemia. J Cell Physiol. 215(3):771–781.
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 8(12):958–969.
   PubMed Web of Science ®Google Scholar
• Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, Markovic M, Honeck H, Luft FC, Schunck W-H. 2007. Mouse Cyp4a isoforms: enzymatic properties, gender-and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J. 403(1):109–118.
   PubMed Web of Science ®Google Scholar
• Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 11(11):723–737.
   PubMed Web of Science ®Google Scholar
• Muthalif MM, Benter IF, Karzoun N, Fatima S, Harper J, Uddin MR, Malik KU. 1998. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci U S A. 95(21):12701–12706.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Sadoshima J. 2018. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 15(7):387–407. doi:10.1038/s41569-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Neckář J, Hye Khan MA, Gross GJ, Cyprová M, Hrdlička J, Kvasilová A, Falck JR, Campbell WB, Sedláková L, Škutová Š, et al. 2019. Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clin Sci. 133(8):939–951.
   Web of Science ®Google Scholar
• Newman JW, Morisseau C, Hammock BD. 2005. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res. 44(1):1–51.
   PubMed Web of Science ®Google Scholar
• Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz DL. 2007. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor α. Drug Metab Dispos. 35(7):1126–1134.
   PubMed Web of Science ®Google Scholar
• Nithipatikom K, Brody DM, Tang AT, Manthati VL, Falck JR, Williams CL, Campbell WB. 2010. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci. 101(12):2629–2636.
   PubMed Web of Science ®Google Scholar
• Nithipatikom K, Gross ER, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ. 2004. Inhibition of cytochrome P450ω-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res. 95(8):e65–e71.
   PubMed Web of Science ®Google Scholar
• Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. 1999. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285(5431):1276–1279.
   PubMed Web of Science ®Google Scholar
• Norwood S, Liao J, Hammock BD, Yang G-Y. 2010. Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Am J Transl Res. 2(4):447–457.
   PubMed Web of Science ®Google Scholar
• Omura T, Tanaka Y, Miyata N, Koizumi C, Sakurai T, Fukasawa M, Hachiuma K, Minagawa T, Susumu T, Yoshida S, et al. 2006. Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke. 37(5):1307–1313.
   PubMed Web of Science ®Google Scholar
• Pace S, Sautebin L, Werz O. 2017. Sex-biased eicosanoid biology: impact for sex differences in inflammation and consequences for pharmacotherapy. Biochem Pharmacol. 145:1–11.
   PubMed Web of Science ®Google Scholar
• Pang W, Li N, Ai D, Niu X, Guan Y, Zhu Y. 2011. Activation of peroxisome proliferator‐activated receptor‐γ downregulates soluble epoxide hydrolase in cardiomyocytes. Clin Exp Pharmacol Physiol. 38(6):358–364.
   PubMed Web of Science ®Google Scholar
• Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, et al. 2012. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest. 122(1):178–191.
   PubMed Web of Science ®Google Scholar
• Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC. 2011. EET signaling in cancer. Cancer Metastasis Rev. 30(3–4):525–540.
   PubMed Web of Science ®Google Scholar
• Parmentier J-H, Muthalif MM, Saeed AE, Malik KU. 2001. Phospholipase D activation by norepinephrine is mediated by 12 (S)-, 15 (S)-, and 20-hydroxyeicosatetraenoic acids generated by stimulation of cytosolic phospholipase A2: tyrosine phosphorylation of phospholipase D2 in response to norepinephrine. J Biol Chem. 276(19):15704–15711.
   PubMed Web of Science ®Google Scholar
• Pascale JV, Lucchesi PA, Garcia V. 2021. Unraveling the role of 12-and 20-HETE in cardiac pathophysiology: G-protein– coupled receptors, pharmacological inhibitors, and transgenic approaches. J Cardiovasc Pharmacol. 77(6):707–717.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Wu HD, Willerson JT, Yeh ETH. 2000. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator–activated receptor-γ activators. Circulation. 101(3):235–238.
   PubMed Web of Science ®Google Scholar
• Patten RD, Hall-Porter MR. 2009. Small animal models of heart failure: development of novel therapies, past and present. Circ Heart Fail. 2(2):138–144.
   PubMed Web of Science ®Google Scholar
• Pfister SL, Gauthier KM, Campbell WB. 2010. Vascular pharmacology of epoxyeicosatrienoic acids. Adv Pharmacol. 60:27–59.
   PubMedGoogle Scholar
• Pokreisz P, Fleming I, Kiss L, Barbosa-Sicard E, Fisslthaler B, Falck JR, Hammock BD, Kim I-H, Szelid Z, Vermeersch P, et al. 2006. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension. 47(4):762–770.
   PubMed Web of Science ®Google Scholar
• Powell WS, Rokach J. 2015. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochim Biophys Acta (BBA) Molecular Cell Biol Lipids. 1851(4):340–355.
   PubMed Web of Science ®Google Scholar
• Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, Falck JR, Capdevila JH. 2005. Characterization of 5, 6-and 8, 9-epoxyeicosatrienoic acids (5, 6-and 8, 9-EET) as potent in vivo angiogenic lipids. J Biol Chem. 280(29):27138–27146.
   PubMed Web of Science ®Google Scholar
• Prasad S, Ravindran J, Aggarwal BB. 2010. NF-κB and cancer: how intimate is this relationship. Mol Cell Biochem. 336(1–2):25–37.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Kararigas G. 2017. Mechanistic pathways of sex differences in cardiovascular disease. Physiol Rev. 97(1):1–37.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U, Hetzer R. 2010. Sex and gender differences in myocardial hypertrophy and heart failure. Circ J. 74(7):1265–1273.
   PubMed Web of Science ®Google Scholar
• Renic M, Klaus JA, Omura T, Kawashima N, Onishi M, Miyata N, Koehler RC, Harder DR, Roman RJ. 2009. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 29(3):629–639.
   PubMed Web of Science ®Google Scholar
• Renton KW. 2004. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab. 5(3):235–243.
   PubMed Web of Science ®Google Scholar
• Revermann M, Mieth A, Popescu L, Paulke A, Wurglics M, Pellowska M, Fischer AS, Steri R, Maier TJ, Schermuly RT, et al. 2011. A pirinixic acid derivative (LP105) inhibits murine 5‐lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm. Br J Pharmacol. 163(8):1721–1732.
   PubMed Web of Science ®Google Scholar
• Roederer MW. 2009. Cytochrome P450 enzymes and genotype-guided drug therapy. Curr Opin Mol Ther. 11(6):632–640.
   PubMedGoogle Scholar
• Roman RJ. 2002. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 82(1):131–185.
   PubMed Web of Science ®Google Scholar
• Rompe F, Artuc M, Hallberg A, Alterman M, Ströder K, Thöne-Reineke C, Reichenbach A, Schacherl J, Dahlöf B, Bader M, et al. 2010. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor κB. Hypertension. 55(4):924–931.
   PubMed Web of Science ®Google Scholar
• Sacerdoti D, Colombrita C, Di Pascoli M, Schwartzman ML, Bolognesi M, Falck JR, Gatta A, Abraham NG. 2007. 11, 12-Epoxyeicosatrienoic acid stimulates heme-oxygenase-1 in endothelial cells. Prostaglandins Other Lipid Mediat. 82(1–4):155–161.
   PubMed Web of Science ®Google Scholar
• Sahan-Firat S, Jennings BL, Yaghini FA, Song CY, Estes AM, Fang XR, Farjana N, Khan AI, Malik KU. 2010. 2, 3′, 4, 5′-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. Am J Physiol Circ Physiol. 299(6):H1891–H1901.
   PubMed Web of Science ®Google Scholar
• Samokhvalov V, Jamieson KL, Darwesh AM, Keshavarz-Bahaghighat H, Lee TYT, Edin M, Lih F, Zeldin DC, Seubert JM. 2018. Deficiency of soluble epoxide hydrolase protects cardiac function impaired by LPS-induced acute inflammation. Front Pharmacol. 9:1572.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Hori MT, Hino T, Golub MS, Tuck ML. 1997. Elevated 12-lipoxygenase activity in the spontaneously hypertensive rat. Am J Hypertens. 10(4 Pt 1):371–378.
   PubMed Web of Science ®Google Scholar
• Schmelzer KR, Kubala L, Newman JW, Kim I-H, Eiserich JP, Hammock BD. 2005. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A. 102(28):9772–9777.
   PubMed Web of Science ®Google Scholar
• Sethi G, Sung B, Aggarwal BB. 2008. Nuclear factor-κB activation: from bench to bedside. Exp Biol Med. 233(1):21–31.
   PubMed Web of Science ®Google Scholar
• Shi Z, He Z, Wang DW. 2022. CYP450 epoxygenase metabolites, epoxyeicosatrienoic acids, as novel anti-inflammatory mediators. Molecules. 27(12):3873.
   PubMed Web of Science ®Google Scholar
• Shoieb SM, Dakarapu R, Falck JR, El-Kadi AOS. 2021. Novel synthetic analogues of 19 (S/R)-hydroxyeicosatetraenoic acid exhibit noncompetitive inhibitory effect on the activity of cytochrome P450 1A1 and 1B1. Eur J Drug Metab Pharmacokinet. 46(5):613–624.
   PubMed Web of Science ®Google Scholar
• Shoieb SM, El-Ghiaty MA, Alqahtani MA, El-Kadi AOS. 2020. Cytochrome P450-derived eicosanoids and inflammation in liver diseases. Prostaglandins Other Lipid Mediat. 147:106400.
   PubMed Web of Science ®Google Scholar
• Shoieb SM, El-Kadi AOS. 2018. S-enantiomer of 19-hydroxyeicosatetraenoic acid preferentially protects against angiotensin II-induced cardiac hypertrophy. Drug Metab Dispos. 46(8):1157–1168.
   PubMed Web of Science ®Google Scholar
• Shoieb SM, El-Sherbeni AA, El-Kadi AOS. 2019a. Identification of 19-(S/R) hydroxyeicosatetraenoic acid as the first endogenous noncompetitive inhibitor of cytochrome P450 1B1 with enantioselective activity. Drug Metab Dispos. 47(2):67–70.
   PubMed Web of Science ®Google Scholar
• Shoieb SM, El-Sherbeni AA, El-Kadi AOS. 2019b. Subterminal hydroxyeicosatetraenoic acids: crucial lipid mediators in normal physiology and disease states. Chem Biol Interact. 299:140–150.
   PubMed Web of Science ®Google Scholar
• Silvestre J-S, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic J-M, Swynghedauw B, Delcayre C. 1998. Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem. 273(9):4883–4891.
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. 2000. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 275(51):40504–40510.
   PubMed Web of Science ®Google Scholar
• Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML. 2007. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension. 50(1):123–129.
   PubMed Web of Science ®Google Scholar
• Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. 2005. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A. 102(6):2186–2191.
   PubMed Web of Science ®Google Scholar
• Sonnweber T, Pizzini A, Nairz M, Weiss G, Tancevski I. 2018. Arachidonic acid metabolites in cardiovascular and metabolic diseases. IJMS. 19(11):3285.
   Web of Science ®Google Scholar
• Spector AA, Norris AW. 2007. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol. 292(3):C996–1012.
   PubMed Web of Science ®Google Scholar
• Stevenson MD, Canugovi C, Vendrov AE, Hayami T, Bowles DE, Krause K-H, Madamanchi NR, Runge MS. 2019. NADPH oxidase 4 regulates inflammation in ischemic heart failure: role of soluble epoxide hydrolase. Antioxid Redox Signal. 31(1):39–58.
   PubMed Web of Science ®Google Scholar
• Sudhahar V, Shaw S, Imig JD. 2010. Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem. 17(12):1181–1190.
   PubMed Web of Science ®Google Scholar
• Sunman JA, Hawke RL, LeCluyse EL, Kashuba ADM. 2004. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos. 32(3):359–363.
   PubMed Web of Science ®Google Scholar
• Takeda N, Manabe I. 2011. Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. Int J Inflam. 2011:535241.
   PubMedGoogle Scholar
• Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, Lee CR. 2011. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab Dispos. 39(1):22–29.
   PubMed Web of Science ®Google Scholar
• Thum T, Borlak J. 2000. Gene expression in distinct regions of the heart. Lancet. 355(9208):979–983.
   PubMed Web of Science ®Google Scholar
• Tian Y. 2009. Ah receptor and NF-κB interplay on the stage of epigenome. Biochem Pharmacol. 77(4):670–680.
   PubMed Web of Science ®Google Scholar
• Tsai M-J, Chang W-A, Tsai P-H, Wu C-Y, Ho Y-W, Yen M-C, Lin Y-S, Kuo P-L, Hsu Y-L. 2017. Montelukast induces apoptosis-inducing factor-mediated cell death of lung cancer cells. IJMS. 18(7):1353.
   Web of Science ®Google Scholar
• Tsao C-C, Foley J, Coulter SJ, Maronpot R, Zeldin DC, Goldstein JA. 2000. CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. Mol Pharmacol. 58(2):279–287.
   PubMed Web of Science ®Google Scholar
• Tunctan B, Korkmaz B, Buharalioglu CK, Firat SS, Anjaiah S, Falck J, Roman RJ, Malik KU. 2008. A 20-hydroxyeicosatetraenoic acid agonist, N-[20-hydroxyeicosa-5 (Z), 14 (Z)-dienoyl] glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. Shock. 30(3):329–335.
   PubMed Web of Science ®Google Scholar
• Tunctan B, Senol SP, Temiz-Resitoglu M, Yilmaz DE, Guden DS, Bahceli O, Horat MF, Sahan-Firat S, Sari AN, Falck JR, et al. 2022. Activation of GPR75 signaling pathway contributes to the effect of a 20-HETE mimetic, 5, 14-HEDGE, to prevent hypotensive and tachycardic responses to lipopolysaccharide in a rat model of septic shock. J Cardiovasc Pharmacol. 80(2):276–293.
   PubMed Web of Science ®Google Scholar
• Umannová L, Zatloukalová J, Machala M, Krcmár P, Májková Z, Hennig B, Kozubík A, Vondrácek J. 2007. Tumor necrosis factor-α modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver “stem-like” cells. Toxicol Sci. 99(1):79–89.
   PubMed Web of Science ®Google Scholar
• Vacková Š, Kikerlová S, Melenovsky V, Kolář F, Imig JD, Kompanowska-Jezierska E, Sadowski J, Červenka L. 2019. Altered renal vascular responsiveness to vasoactive agents in rats with angiotensin II-dependent hypertension and congestive heart failure. Kidney Blood Press Res. 44(4):792–809.
   PubMed Web of Science ®Google Scholar
• Van den Akker F, De Jager SCA, Sluijter JPG. 2013. Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. Mediators Inflamm. 2013:181020.
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. 2010. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 11(10):700–714.
   PubMed Web of Science ®Google Scholar
• VanRollins M, Baker RC, Sprecher HW, Murphy RC. 1984. Oxidation of docosahexaenoic acid by rat liver microsomes. J Biol Chem. 259(9):5776–5783.
   PubMed Web of Science ®Google Scholar
• Velten M, Duerr GD, Pessies T, Schild J, Lohner R, Mersmann J, Dewald O, Zacharowski K, Klaschik S, Hilbert T, et al. 2012. Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice. Cardiovasc Res. 96(3):422–432.
   PubMed Web of Science ®Google Scholar
• Vitale C, Mendelsohn ME, Rosano G. 2009. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol. 6(8):532–542.
   PubMed Web of Science ®Google Scholar
• von Jeinsen B, Watrous J, Henglin M, Rong J, Niiranen TJ, Vasan RS, Larson MG, Jain M, Cheng S. 2017. Eicosanoid variation may contribute to sex differences in cardiovascular risk. Circulation. 136(suppl_1):A19156–A19156.
   Google Scholar
• Wallukat G, Morwinski R, Kühn H. 1994. Modulation of the beta-adrenergic response of cardiomyocytes by specific lipoxygenase products involves their incorporation into phosphatidylinositol and activation of protein kinase C. J Biol Chem. 269(46):29055–29060.
   PubMed Web of Science ®Google Scholar
• Wang B, Zeng H, Wen Z, Chen C, Wang DW. 2016. CYP 2J2 and its metabolites (epoxyeicosatrienoic acids) attenuate cardiac hypertrophy by activating AMPK α2 and enhancing nuclear translocation of Akt1. Aging Cell. 15(5):940–952.
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. 2012. Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer. J Clin Invest. 122(1):19–22.
   PubMed Web of Science ®Google Scholar
• Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW, Zeldin DC. 2003. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther. 307(2):753–764.
   PubMed Web of Science ®Google Scholar
• Wang N, Verna L, Chen N-G, Chen J, Li H, Forman BM, Stemerman MB. 2002. Constitutive activation of peroxisome proliferator-activated receptor-γ suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 277(37):34176–34181.
   PubMed Web of Science ®Google Scholar
• Wang W, Lu M. 1995. Effect of arachidonic acid on activity of the apical K + channel in the thick ascending limb of the rat kidney. J Gen Physiol. 106(4):727–743.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, Zeldin DC. 2005. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther. 314(2):522–532.
   PubMed Web of Science ®Google Scholar
• Wang Z-H, B Davis B, Jiang D-Q, Zhao T-T, Xu D-Y. 2013. Soluble epoxide hydrolase inhibitors and cardiovascular diseases. Curr Vasc Pharmacol. 11(1):105–111.
   PubMed Web of Science ®Google Scholar
• Wen Y, Gu J, Liu Y, Wang PH, Sun Y, Nadler JL. 2001. Overexpression of 12-lipoxygenase causes cardiac fibroblast cell growth. Circ Res. 88(1):70–76.
   PubMed Web of Science ®Google Scholar
• Wen Y, Gu J, Peng X, Zhang G, Nadler J. 2003. Overexpression of 12-lipoxygenase and cardiac fibroblast hypertrophy. Trends Cardiovasc Med. 13(4):129–136.
   PubMed Web of Science ®Google Scholar
• Wu J, Dai F, Li C, Zou Y. 2020. Gender differences in cardiac hypertrophy. J Cardiovasc Transl Res. 13(1):73–84.
   PubMed Web of Science ®Google Scholar
• Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. 1996. Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart (∗). J Biol Chem. 271(7):3460–3468.
   PubMed Web of Science ®Google Scholar
• Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai H-J, Kim I-H, Tuteja D, Mateo RKP, Singapuri A, et al. 2006. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A. 103(49):18733–18738.
   PubMed Web of Science ®Google Scholar
• Xu L, Brink M. 2016. mTOR, cardiomyocytes and inflammation in cardiac hypertrophy. Biochim Biophys Acta (BBA) Molecular Cell Res. 1863(7):1894–1903.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang XA, Wang DW. 2011. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev. 63(8):597–609.
   PubMed Web of Science ®Google Scholar
• Yaghi A, Sims SM. 2005. Constrictor-induced translocation of NFAT3 in human and rat pulmonary artery smooth muscle. Am J Physiol Lung Cell Mol Physiol. 289(6):L1061–L1074.
   PubMed Web of Science ®Google Scholar
• Yang F, Dong A, Mueller P, Caicedo J, Sutton AM, Odetunde J, Barrick CJ, Klyachkin YM, Abdel-Latif A, Smyth SS. 2012. Coronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells. PLoS One. 2012;7(8):e40196.
   Google Scholar
• Yousif MHM, Benter IF, Roman RJ. 2009. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Auton Autacoid Pharmacol. 29(1–2):33–41.
   PubMedGoogle Scholar
• Yu S, Reddy JK. 2007. Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta (BBA) Molecular Cell Biol Lipids. 1771(8):936–951.
   PubMed Web of Science ®Google Scholar
• Zeldin DC, Dubois RN, Falck JR, Capdevila JH. 1995. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys. 322(1):76–86.
   PubMed Web of Science ®Google Scholar
• Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, Wu S. 1996. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys. 330(1):87–96.
   PubMed Web of Science ®Google Scholar
• Zeldin DC. 2001. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 276(39):36059–36062.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Han Y, Bao Y, Li W, Li X, Shen X, Wang X, Yao F, O'Rourke ST, Sun C. 2010. 20-HETE increases NADPH oxidase-derived ROS production and stimulates the L-type Ca2+ channel via a PKC-dependent mechanism in cardiomyocytes. Am J Physiol Heart Circ Physiol. 299(4):H1109–H1117.
   PubMed Web of Science ®Google Scholar
• Zhang B, Cao H, Rao GN. 2006. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14, 15-epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem. 281(2):905–914.
   PubMed Web of Science ®Google Scholar
• Zhang F, Deng H, Kemp R, Singh H, Gopal VR, Falck JR, Laniado-Schwartzman M, Nasjletti A. 2005. Decreased levels of cytochrome P450 2E1–derived eicosanoids sensitize renal arteries to constrictor agonists in spontaneously hypertensive rats. Hypertension. 45(1):103–108.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Y, Chen M, Su X, Yi D, Lu P, Zhu D. 2014. 15‐LO/15‐HETE mediated vascular adventitia fibrosis via p38 MAPK‐dependent TGF‐β. J Cell Physiol. 229(2):245–257.
   PubMed Web of Science ®Google Scholar
• Zhang M, Shu H, Chen C, He Z, Zhou Z, Wang DW. 2022. Epoxyeicosatrienoic acid: a potential therapeutic target of heart failure with preserved ejection fraction. Biomed Pharmacother. 153:113326.
   PubMed Web of Science ®Google Scholar
• Zhang Y, El-Sikhry H, Chaudhary KR, Batchu SN, Shayeganpour A, Jukar TO, Bradbury JA, Graves JP, DeGraff LM, Myers P, et al. 2009. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 297(1):H37–H46.
   PubMed Web of Science ®Google Scholar
• Zhao G, Wang J, Xu X, Jing Y, Tu L, Li X, Chen C, Cianflone K, Wang P, Dackor RT, et al. 2012. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-α-induced injury. J Lipid Res. 53(3):456–466.
   PubMed Web of Science ®Google Scholar
• Zhao X, Quigley JE, Yuan J, Wang M-H, Zhou Y, Imig JD. 2006. PPAR-α activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol. 290(6):H2187–H2195.
   PubMed Web of Science ®Google Scholar
• Zhou B, Wang X, Li F, Wang Y, Yang L, Zhen X, Tan W. 2017. Mitochondrial activity and oxidative stress functions are influenced by the activation of AhR-induced CYP1A1 overexpression in cardiomyocytes. Mol Med Rep. 16(1):174–180.
   PubMed Web of Science ®Google Scholar
• Zhou C, Huang J, Chen J, Lai J, Zhu F, Xu X, Wang DW. 2016. CYP2J2-derived EETs attenuated angiotensin II-induced adventitial remodeling via reduced inflammatory response. Cell Physiol Biochem. 39(2):721–739.
   PubMedGoogle Scholar
• Zhou Y, Khan H, Xiao J, Cheang WS. 2021. Effects of arachidonic acid metabolites on cardiovascular health and disease. IJMS. 22(21):12029.
   Web of Science ®Google Scholar
• Zhu Y, Schieber EB, McGiff JC, Balazy M. 1995. Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension. 25(4 Pt 2):854–859.
   PubMed Web of Science ®Google Scholar
• Zordoky BNM, Aboutabl ME, El-Kadi AOS. 2008. Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab Dispos. 36(11):2277–2286.
   PubMed Web of Science ®Google Scholar
• Zordoky BNM, Anwar-Mohamed A, Aboutabl ME, El-Kadi AOS. 2010. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol. 242(1):38–46.
   PubMed Web of Science ®Google Scholar
• Zordoky BNM, El-Kadi AOS. 2009. Role of NF-κB in the regulation of cytochrome P450 enzymes. Curr Drug Metab. 10(2):164–178.
   PubMed Web of Science ®Google Scholar
• Zordoky BNM, El-Kadi AOS. 2010. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 125(3):446–463.
   PubMed Web of Science ®Google Scholar